Beyond single-agent activity, alisertib synergizes with BET inhibitors such as JQ1 to enhance N-Myc degradation and suppress tumor growth in preclinical models (Brockmann et al., 2013; Yi et al., 2021). The gene discussed is MYCN; the disease is neoplasm.